S-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: Involvement possibility of inhibition of survival signal, Akt/PKB

Cancer Letters

Volumn 226, Issue 2, 2005, Pages 161-168

  Harada, Koji ^a   Kawaguchi, Shin Ichi ^a   Supriatno, ^a   Kawashima, Yuichiro ^a   Yoshida, Hideo ^a   Sato, Mitsunobu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Akt PKB; Apoptosis; Radiation; S 1; Survival signal

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; FLUOROPYRIMIDINE DERIVATIVE; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MOUSE; MOUTH CANCER; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; DRUG COMBINATIONS; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MICE; MICE, NUDE; MOUTH NEOPLASMS; OXONIC ACID; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; RADIATION-SENSITIZING AGENTS; TEGAFUR;

EID: 22844449688     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.12.048     Document Type: Article

References (25)

1. T. Shirasaka, Y. Shimamato, H. Ohshimo, M. Yamaguchi, T. Kato, and K. Yonekura Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 1996 548 557
2. M. Fukushima, H. Satake, J. Uchida, Y. Shimamoto, T. Kato, and T. Takechi Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts Int. J. Oncol. 13 1998 693 698
3. M. Fukushima, Y. Shimamoto, T. Kato, J. Uchida, R. Yonekura, and H. Ohshimo Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil Anticancer Drugs 9 1998 817 823
4. Y. Sakata, A. Ohtsu, N. Horikoshi, K. Sugimachi, Y. Mitachi, and T. Taguchi Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur. J. Cancer 34 1998 1715 1720
5. M. Kawahara, K. Furuse, Y. Segawa, K. Yoshimori, K. Matsui, and S. Kudoh Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer Br. J. Cancer 85 2001 939 943
6. S.J. Cohen, C.G. Leichman, G. Yeslow, M. Beard, A. Proefrock, and B. Roedig Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer Clin. Cancer Res. 8 2002 2116 2122
7. Y. Inuyama, A. Kida, M. Tsukuda, N. Kohno, and B. Satake Late phase II study of S-1 in patients with advanced head and neck cancer Gan To Kagaku Ryoho 28 2001 1381 1390
8. K. Harada, S. Kawaguchi, Supriatno, T. Onoue, H. Yoshida, and M. Sato Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells Oral Oncol. 40 2004 713 719
9. S. Barnes, and T.G. Peterson Biochemical target of the isoflavone genistein in tumor cell lines Proc. Soc. Exp. Biol. Med. 208 1995 103 108
10. C.M. Linassier, M. Pierre, J.B.L. Pecq, and J. Pierre Mechanism of action in NIH3T3 cells of genistein, an inhibitor of EGF receptor tyrosine kinase activity Biochem. Pharmacol. 39 1990 187 193
11. T.G. Peterson, and S. Barnes Isoflavones inhibited the growth of human prostate cell lines without inhibiting epidermal growth factor receptor autophosphorylation Prostate 22 1993 335 345
12. R. Yaka, A. Gamliel, D. Gurwitz, and R. Stein NCF induces transient but not sustained activation of ERK in PC12 mutant cells incapable of differentiating J. Cell. Biochem. 70 1998 425 432
13. Z.M. Shao, M. Alpaugh, J.A. Fontana, and S.H. Barsky Genistein inhibits cell proliferation similarly in ER-positive and ER-negative human breast carcinoma cell lines characterized by p21WAF1/CIP1 induction, G2/M arrest and apoptosis J. Cell. Biochem. 69 1998 44 54
14. Y. Li, S. Upadhyay, M. Bhuiyan, and F.H. Sarkar Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein Oncogene 18 1999 3166 3172
15. D.A. Cross, D.R. Alessi, P. Cohen, M, Andjelkovich, and B.A. Hemmings Inhibition of glycogen synthase kinase-3 by insulin mediated by protein Nature 378 1995 785 789
16. Kip1 induces growth arrest and apoptosis in an oral cancer cell line Oral Oncol. 38 2002 730 736
17. Y. Gavrieli, Y. Sherman, and S.A. Ben-Sasson Identification of programmed cell death in situ specific labeling of nuclear DNA fragmentation J. Cell. Biol. 119 1992 493 501
18. M. Hockel, K. Schlenger, M. Mitze, U. Schaffer, and P. Vaupel Hypoxia and radiation response in human tumors Semin. Radiat. Oncol. 6 1996 3 9
19. S. Shintani, M. Mihara, C. Li, Y. Nakahara, S. Hino, K. Nakashiro, and H. Hamakawa Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma Cancer Sci. 94 2003 894 900
20. J.M. Lee, and A. Berstein p53 mutations increase resistance to ionizing radiation Proc. Natl Acad. Sci. USA 90 1993 5742 5746
21. K.M. Nicholson, and N.G. Anderson The protein kinase B/Akt signalling pathway in human malignancy Cell. Signal. 14 2002 381 395
22. G. Wang, E. Reed, and Q.Q. Li Apoptosis in prostate cancer: progressive and therapeutic implications (Review) Int. J. Mol. Med. 14 2004 23 34
23. Southeast Sweden Breast Cancer Group G. Perez-Tenorio, and O. Stal Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients Br. J. Cancer 86 2002 540 545
24. J.A. Vrana, S. Grant, and P. Dent Inhibition of the MAPK pathway abrogates BCL2-mediated survival of leukemia cells after exposure to low-dose ionizing radiation Radiat. Res. 151 1999 559 569
25. K. Harada, S. Kawaguchi, Supriatno, T. Onoue, H. Yoshida, M. Sato, Enhancement of apoptosis in salivary gland cancer cells by the combination of oral fluoropyrimidine anti-cancer agent (S-1) and radiation, Int. J. Oncol. 25 (2004) 905-911.